The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Open accessPublished version of a preprint
Abstract
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma, but the fraction of patients who derive clinical benefit remains undefined. Here, we report the experience of 860 patients with metastatic lung adenocarcinoma analyzed prospectively for mutations in >300 cancer-associated genes. Potentially actionable genetic events were stratified into one of four levels based upon published clinical or laboratory evidence that the mutation in question confers increased sensitivity to standard or investigational therapies. Overall, 37.1% (319/860) of patients received a matched therapy guided by their tumor molecular profile. Excluding alterations associated with standard-of-care therapy, 14.4% (69/478) received matched therapy, with a clinical benefit of 52%. Use of matched therapy was strongly influenced by the level of preexistent clinical evidence that the mutation identified predicts for drug response. Analysis of genes mutated significantly more often in tumors without known actionable mutations nominated STK11 and KEAP1 as possible targetable mitogenic drivers. Significance: An increasing number of therapies that target molecular alterations required for tumor maintenance and progression have demonstrated clinical activity in patients with lung adenocarcinoma. The data reported here suggest that broader, early testing for molecular alterations that have not yet been recognized as standard-of-care predictive biomarkers of drug response could accelerate the development of targeted agents for rare mutational events and could result in improved clinical outcomes. Cancer Discov; 7(6); 596–609. ©2017 AACR. See related commentary by Liu et al., p. 555. This article is highlighted in the In This Issue feature, p. 539
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [21]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Somatic mutations in LKB1 and KEAP1 significantly co-occur with mutant KRAS and with each other in NSCLC15, 59, 63, 91.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Although EGFR –mutant tumors represent the prototypical oncogene-addicted LUAD subgroup that spearheaded adoption of the single-driver model, the overwhelming majority of EGFR-mutant lung tumors harbor one or more co-mutations, even when the analysis is limited to pre-defined sets of cancer-relevant genes within established panels (FoundationOne, Guardant360, MSK-IMPACT)15, 59, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- OncoKB.org, 2016, Precision Oncology Knowledge Base [Internet]
- Banno, 2016, : 10.1111/.12980, Sensitivities to various EGFR-TKIs of uncommon EGFR mutations L861Q and S768I: what is the optimal EGFR-TKI?, Cancer Sci · DOI
Cited by
Sorted by citations
Items 301–400 of 645
Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations
Ding, W., Yang, P., Zhao, X., Wang, X., Liu, H., Su, Q., Wang, X., Li, J., Gong, Z., Zhang, D., et al. (2024) · Respiratory Research · doi:10.1186/s12931-023-02656-3 · Cited by 17
FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy
Darwis, N. D. M., Nachankar, A., Sasaki, Y., Matsui, T., Noda, S., Murata, K., Tamaki, T., Ando, K., Okonogi, N., Shiba, S., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184563 · Cited by 15
Somade, O. T., Ajayi, B. O., Adeyi, O. E., Adeshina, A., Adekoya, M. O., & Abdulhameed, R. O. (2020) · Metabolism Open · doi:10.1016/j.metop.2020.100075 · Cited by 18
Li, W., Feng, S., Wu, H., Deng, J., Zhou, W.-Y., Jia, M., Shi, Y., Ma, L., Zeng, X., Zuberi, Z., et al. (2022) · Cells · doi:10.3390/cells11071220 · Cited by 15
Tian, T., Li, Y., Li, J., Xu, J., Fan, H., Zhu, J., Wang, Y., Peng, F., Gong, Y., Du, Y., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-116 · Cited by 17
Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma
Liu, D., Vokes, N. I., & Allen, E. M. V. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0355 · Cited by 14
Possible application of circulating free tumor DNA in non-small cell lung cancer patients
Karachaliou, N., Sosa, A. E., Molina‐Vila, M. Á., Ruiz, M. C., & Rosell, R. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.09.59 · Cited by 14
Oncologist uptake of comprehensive genomic profile guided targeted therapy
Nesline, M., DePietro, P., Dy, G. K., Early, A., Papanicolau‐Sengos, A., Conroy, J. M., Lenzo, F. L., Glenn, S. T., Chen, H., Grand’Maison, A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27047 · Cited by 14
Han, P., Liu, Q., & Xiang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.11163 · Cited by 14
Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations
Hayashi, T., Kohsaka, S., Takamochi, K., Hara, K., Kishikawa, S., Sano, K., Takahashi, F., Suehara, Y., Saito, T., Takahashi, K., et al. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.07.007 · Cited by 14
Shi, J., Yang, F., Zhou, N., Jiang, Y. Y., Zhao, Y., Zhu, J., Prelaj, A., Malhotra, J. D., Normanno, N., Danese, E., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-219 · Cited by 14
Watanabe, S., Sakai, K., Matsumoto, N., Koshio, J., Ishida, A., Abe, T., Ishikawa, D., Tanaka, T., Aoki, A., Kajiwara, T., et al. (2022) · Cancers · doi:10.3390/cancers15010204 · Cited by 14
Park, S., Kim, T. M., Cho, S., Kim, S., Oh, Y., Kim, M., Keam, B., Kim, D., & Heo, D. S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.018 · Cited by 14
High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma
Chang, S., Zhu, Y., Xi, Y., Gao, F., Lü, J., Dong, L., Ma, C., & Li, H. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s329482 · Cited by 13
Huang, R., Huang, Y.-L., An, N., Hu, J., Wu, C., Chen, Y., Chen, J., Zhao, Q., Xu, R., Yuan, S. Q., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103494 · Cited by 14
Bruehl, F. K., Doxtader, E. E., Cheng, Y., Farkas, D. H., Farver, C. F., & Mukhopadhyay, S. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207421 · Cited by 13
Koga, T., Suda, K., Nishino, M., Fujino, T., Ohara, S., Hamada, A., Soh, J., Tirunagaru, V. G., Vellanki, A., Doebele, R. C., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-216 · Cited by 12
Spagnuolo, A., Maione, P., & Gridelli, C. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-948 · Cited by 15
Federico, A. D., Giglio, A. D., Gelsomino, F., de Biase, D., Giunchi, F., Palladini, A., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · Cancers · doi:10.3390/cancers14143472 · Cited by 15
Li, Y., & Niu, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-20040-x · Cited by 13
Chen, H., Wang, B., Zhang, Y., Shu, Y., Dong, H., Zhao, Q. C., Yang, C., Li, J., Duan, X., & Zhou, Q. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24977 · Cited by 13
Oncogenic Effect of the Novel Fusion Gene VAPA-Rab31 in Lung Adenocarcinoma
Yoon, D., Bae, K., Kim, J.-H., Choi, Y., & Yoon, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092309 · Cited by 13
Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology
Tao, J. J., Eubank, M. H., Schram, A. M., Cangemi, N. A., Pamer, E. G., Rosen, E. Y., Schultz, N. D., Chakravarty, D., Philip, J., Hechtman, J. F., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00066 · Cited by 13
Self-citationAnalytic inquiry: Molecular testing in lung cancer
Zakowski, M. F. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21866 · Cited by 12
Polk, J. B., Campbell, J., Drilon, A. E. D. C., Keating, P., & Cambrosio, A. (2023) · Social Science & Medicine · doi:10.1016/j.socscimed.2023.115789 · Cited by 12
Self-citationMolecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01349-1 · Cited by 13
Multi-Omics Mining of lncRNAs with Biological and Clinical Relevance in Cancer
Salido-Guadarrama, I., Romero-Cordoba, S. L., & Rueda-Zarazúa, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316600 · Cited by 11
Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR -Mutant Non–Small Cell Lung Cancer
Wang, S., Lai, J.-C., Li, Y., Tang, C., Lu, J., Han, M. S., Ye, X., Jia, L., Cui, W., Yang, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1817 · Cited by 12
Hayashi, T., Kohsaka, S., Takamochi, K., Kishikawa, S., Ikarashi, D., Sano, K., Hara, K., Onagi, H., Suehara, Y., Takahashi, F., et al. (2020) · Histopathology · doi:10.1111/his.14311 · Cited by 12
Sun, L., Li, M., Deng, L., Niu, Y., Tang, Y., Wang, Y., & Guo, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.625593 · Cited by 13
Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer
Al-Obeidi, E., Riess, J. W., Malapelle, U., Rolfo, C. D., & Gandara, D. R. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.005 · Cited by 12
Dagogo‐Jack, I., Robinson, H. E., Mino-Kenudson, M. A., Farago, A. F., Kamesan, V., Iafrate, A. J., Shaw, A. T., & Lennerz, J. K. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.032 · Cited by 12
Laliotis, G., Chavdoula, E., Paraskevopoulou, M. D., Kaba, A., Ferlita, A. L., Singh, S. V., Anastas, V., Nair, K. A., Orlacchio, A., Taraslia, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24795-1 · Cited by 14
RetractedMarcoux, P. J., Hwang, J. W., Desterke, C., Imeri, J., Griscelli, A. B., & Turhan, A. G. (2023) · Cells · doi:10.3390/cells12242847 · Cited by 11
Serna‐Blasco, R., Sánchez‐Herrero, E., Sanz‐Moreno, S., Rodríguez-Festa, A., García‐Veros, E., Casarrubios, M., Sierra‐Rodero, B., Briviesca, R. L., Cruz‐Bermúdez, A., Mielgo-Rubio, X., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100279 · Cited by 12
Differential Diagnostic Value of Histology in MPLC and IPM: A Systematic Review and Meta-Analysis
Tian, S., Li, F., Pu, J., Zheng, Y., Shi, H., Dong, Y., Chen, R., & Bai, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871827 · Cited by 11
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
Dagogo‐Jack, I., & Ritterhouse, L. L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-2019-cnsclc-09 · Cited by 11
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
Eklund, E. Ä., Svensson, J. B., Näslund, L. S., Yhr, M., Sayin, S. I., Wiel, C., Akyürek, L. M., Torstensson, P., Sayin, V. I., Hallqvist, A., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03342-6 · Cited by 9
A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib
Kunte, S., & Stevenson, J. P. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.005 · Cited by 10
Jiang, J., Tang, C., Li, Y., Lin, Z., Li, Z., Zhou, C., Gu, Y., He, P., Tang, Q., Zhang, Y., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.11.012 · Cited by 10
Leone, A., Muscarella, L. A., Graziano, P., Tornese, A., Grillo, L. R., Lorenzo, A. D., Bronzini, M., Scarpino, S., Sparaneo, A., & Rossi, G. (2022) · Cancers · doi:10.3390/cancers15010292 · Cited by 10
Kato, S., Hayashi, T., Suehara, Y., Hamanoue, H., Yamanaka, S., Ichikawa, Y., Higurashi, T., Ohashi, K., Yamaguchi, S., Nozaki, Y., et al. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy173 · Cited by 10
Decoupling of Nrf2 Expression Promotes Mesenchymal State Maintenance in Non-Small Cell Lung Cancer
Haley, J. D., Ruiz, C. F., Montal, E. D., Wang, D., Haley, J. D., & Girnun, G. D. (2019) · Cancers · doi:10.3390/cancers11101488 · Cited by 10
Immunotherapy in oncogene addicted non-small cell lung cancer
McLean, L. S., Leal, J. L., Solomon, B., & John, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-772 · Cited by 11
Gao, L., & Shen, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.890247 · Cited by 11
A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review
Sharma, P., Mahadevia, H. J., Donepudi, S., Kujtan, L. A., Gustafson, B., Ponvilawan, B., Al‐Obaidi, A., Subramanian, J., & Bansal, D. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.04.009 · Cited by 9
Liu, H., Zhou, C., Lü, J., Liu, Y., Zou, P., Zhu, L., Lei, H.-M., & Han, B. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07687-w · Cited by 9
Xiao, L., Guan, R., Zhu, J., Meng, Y., Zhu, J., Yang, Y., Cui, Y., Dai, J., Mao, W., Lv, L., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05104-3 · Cited by 10
NCAPH is negatively associated with Mcl‑1 in non‑small cell lung cancer
Xiong, Q., Fan, S., Duan, L., Liu, B., Jiang, X., Chen, X., Xiong, C., Tao, Q., Wang, J., Zhang, H., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11359 · Cited by 9
A fusion of CD63–BCAR4 identified in lung adenocarcinoma promotes tumorigenicity and metastasis
Bae, K., Kim, J. H., Jung, H., Kong, S., Kim, Y., Kim, S., Lee, G. K., Lee, J. S., Lee, J. J.-K., Ju, Y. S., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01146-3 · Cited by 9
Forest, F., Laville, D., Habougit, C., Cruz, V. D., Casteillo, F., Yvorel, V., Bard‐Sorel, S., Godard, W., Picot, T., Tiffet, O., et al. (2021) · Histopathology · doi:10.1111/his.14463 · Cited by 9
Luo, C., He, S., Zhang, H., He, S., Qi, H., & Wei, A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.727307 · Cited by 9
Khalifa, E., Chapusot, C., Tournier, B., Sentis, J., Marion, E., Remond, A., Aubry, M., Pioche, C., Bergeron, A., Primois, C., et al. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208325 · Cited by 9
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes
Dong, X., Huang, D., Yi, X., Zhang, S., Wang, Z., Yan, B., Sham, P. C., Chen, K., & Li, M. J. (2020) · Communications Biology · doi:10.1038/s42003-019-0736-4 · Cited by 9
de Moraes, F. C. A., Pasqualotto, E., Rodrigues, A. L. S. D. O., & Burbano, R. M. R. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03777-4 · Cited by 8
Zeng, M., Hu, Y.-X., Zhao, L., Duan, C.-Z., Wu, H., Xu, Y., Liu, X., Wang, Y., Jiang, D., & Zeng, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117200 · Cited by 8
Construction of the model for predicting prognosis by key genes regulating EGFR-TKI resistance
Zhuge, J., Wang, X., Li, J., Wang, T., Wang, H., Yang, M., Dong, W., & Gao, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.968376 · Cited by 8
Xie, J., Hu, B., Gong, Y., He, S., Lin, J., Huang, Q., & Cheng, J. Q. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04746-8 · Cited by 8
Liu, C., Zheng, S., Wang, S., Wang, X., Feng, X., Sun, N., & He, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006949 · Cited by 7
Stargardter, M., McBride, A., Tosh, J. C., Sachdev, R., Yang, M., Ambavane, A., Mittal, M., Vioix, H., & Liu, F. X. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1942017 · Cited by 8
Saigí, M., Carcereny, E., Morán, T., Cucurull, M., Doménech, M., Hernández, A., Martínez‐Cardús, A., Pros, E., & Sánchez‐Céspedes, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102430 · Cited by 8
Guardiola, S., Sánchez‐Navarro, M., Rosell, R., Giralt, E., & Codony‐Servat, J. (2022) · Medical Oncology · doi:10.1007/s12032-022-01800-1 · Cited by 8
Parisi, A., Rossi, F., Filippis, C. D., Paoloni, F., Felicetti, C., Mammarella, A., Pecci, F., Lupi, A., & Berardi, R. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s272563 · Cited by 8
EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilian population
Laus, A. C., de Paula, F. E., de Lima, M. A., Carlos, C. D., Gomes, I. N. F., Marchi, P. D., Valente, J. K. N., Pioltini, A. B. M., Miziara, J. E., da Silva, C. M., et al. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04702-0 · Cited by 8
Ros, J., Baraibar, I., Vivancos, A. P., & Rodon, J. A. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_19_19 · Cited by 8
Lin, Q., & Yin, H. (2019) · Biotechnology Letters · doi:10.1007/s10529-019-02766-3 · Cited by 8
Jhanwar, S. C., Xu, X. L., Elahi, A. H., & Abramson, D. H. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100723 · Cited by 8
Jia, Z., Xing, J., Li, J., Wang, W., Wang, Y., Song, Y., Yang, X., Xue, J., Ye, J., Li, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-107 · Cited by 7
Self-citationTan, C., Mandell, J. D., Dasari, K., Cannataro, V. L., Alfaro-Murillo, J. A., & Townsend, J. P. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.10.008 · Cited by 7
The landscape of actionable genomic alterations in lung adenocarcinomas in India
Sharma, R., Kamireddy, A. P., Hussaini, S. M., Chatterjee, S., Hasan, Q. A., & Jain, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1256756 · Cited by 7
Zhang, X., Feng, J., Su, X., Yan, L., Wu, W. Y.-Y., & Cheng, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s283617 · Cited by 7
Comprehensive Analysis of Immune-Related Metabolic Genes in Lung Adenocarcinoma
Li, F., Huang, C., Qiu, L., Li, P., Shi, J., & Zhang, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.894754 · Cited by 7
Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins
Yokoo, H., Tsuji, G., Inoué, T., Naito, M., Demizu, Y., & Ohoka, N. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107204 · Cited by 7
Santibáñez-Andrade, M., Quezada-Maldonado, E. M., Quintana-Belmares, R. O., Morales‐Bárcenas, R., Rosas‐Pérez, I., Amador-Muñóz, O., Miranda, J., Sánchez-Pérez, Y., & García-Cuellar, C. M. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.171933 · Cited by 7
Glutamine antagonists may KEAP lung cancer in check
Blatt, E. B., & DeBerardinis, R. J. (2024) · Science Advances · doi:10.1126/sciadv.ado7808 · Cited by 7
Garinet, S., Mansuet‐Lupo, A., Denize, T., Loyaux, R., Timsit, S., Gazeau, B., Fabre, E., Maaradji, Z., Gibault, L., Leprieur, E. G., et al. (2024) · Pathology · doi:10.1016/j.pathol.2024.02.014 · Cited by 7
Molecular Pathology of Lung Cancer
Roy‐Chowdhuri, S. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.002 · Cited by 7
Vieira, I. A., Andreis, T. F., Fernandes, B., Achatz, M. I., Macedo, G. S., Schramek, D., & Ashton‐Prolla, P. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.606537 · Cited by 7
Nkosi, D., Casler, V. L., Syposs, C. R., & Oltvai, Z. N. (2022) · Genes · doi:10.3390/genes13050799 · Cited by 7
Elsakka, A., Petre, E. N., Ridouani, F., Ghosn, M., Bott, M. J., Husta, B., Arcila, M. E., Alexander, E. S., Solomon, S. B., & Ziv, E. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100342 · Cited by 7
Self-citationLiu, Y., Gao, Y. J., Wang, Y., Zhao, C., Zhang, Z., Li, B., & Zhang, T. (2022) · BMC Cancer · doi:10.1186/s12885-022-10236-9 · Cited by 7
Self-citationCanadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Cheema, P. K., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Sacher, A. G., Sheffield, B. S., Snow, S. L., Vincent, M. D., et al. (2023) · Current Oncology · doi:10.3390/curroncol30070476 · Cited by 10
Qin, Z., Zhang, H., Yan, P., Yu, L., Hong, C., Calvetti, L., Passaro, A., Araújo, A., & Chen, Y. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-841 · Cited by 6
Doroshow, D. B., & Doroshow, J. H. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000386 · Cited by 9
Gao, Y., Chen, F., & Zhang, L. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.1906035 · Cited by 7
Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors
Doi, Y., Tagaya, H., Noge, A., & Semba, K. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00919-5 · Cited by 7
Distinct epithelial-to-mesenchymal transitions induced by PIK3CA H1047R and PIK3CB
Gjelaj, E., & Hamel, P. A. (2021) · Journal of Cell Science · doi:10.1242/jcs.248294 · Cited by 6
Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Doe-Tetteh, S. A., Camp, S. Y., Reales, D. N., Crowdis, J. P., Noronha, A. M., Wolff, B., Alano, T., Galle, J., Selçuklu, S. D., Viale, A. J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3247 · Cited by 6
Self-citationGenomic Landscape of NSCLC in the Republic of Ireland
Keogh, R. J., Barr, M. P., Keogh, A., McMahon, D., O’Brien, C. P., Finn, S. P., & Naidoo, J. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100627 · Cited by 6
Zhang, S., Zeng, Z., Qiu, F. X., Li, X., & Xu, X. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101217 · Cited by 6
Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell Lung Cancer
Abdullah, S., Chakraborty, R., Kumkar, P. S., Debnath, B., & Bala, A. (2024) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2024051317 · Cited by 6
Melchior, L. C., Hirschmann, A., Hofman, P. M., Bontoux, C., Concha, Á., Mrabet‐Dahbi, S., Vannuffel, P., Watkin, E., Putzová, M., Scarpino, S., et al. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03778-9 · Cited by 6
Genetic Blueprints in Lung Cancer: Foundations for Targeted Therapies
Dan, A., Burtavel, L. M., Coman, M.-C., Focșa, I. O., Duta-Ion, S. G., Juganaru, I. R., Zaruha, A.-G., Strugari, I.-M., Hotinceanu, I. A., Codreanu, P.-C., et al. (2024) · Cancers · doi:10.3390/cancers16234048 · Cited by 6
MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience
Dhiab, R. B., Loyaux, R., Garinet, S., Bastide, M., Léonard-Goyet, S., Fabre, E., Mansuet‐Lupo, A., Gibault, L., Jouveshomme, S., Leprieur, E. G., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-99541-4 · Cited by 6
The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo
Rackley, B. B., Seong, C.-S., Kiely, E. J., Parker, R. E., Rupji, M., Dwivedi, B., Heddleston, J. M., Giang, W., Anthony, N. R., Chew, T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01663-8 · Cited by 6
Kishikawa, S., Hayashi, T., Saito, T., Takamochi, K., Sasa, K., Suehara, Y., Takahashi, F., Sasahara, N., Kohsaka, S., Suzuki, K., et al. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03247-7 · Cited by 6
Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations
Sabari, J. K., Heymach, J. V., & Sandy, B. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0200 · Cited by 6
Prognostic Value of Genomic Instability of m6A-Related lncRNAs in Lung Adenocarcinoma
Li, R., Li, J., Liu, T., Chen, H., Yao, J., Ji, X.-L., & Qu, Y.-Q. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.707405 · Cited by 6
Jalal, S. I., Guo, A., Ahmed, S., & Kelley, M. J. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.014 · Cited by 6
Metadata
- Authors
- Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., Jayakumaran, G., Gao, S. P., Johnsen, H. C., Hanrahan, A. J., Zehir, A., Rekhtman, N., Ginsberg, M. S., Li, B. T., Yu, H. A., Paik, P. K., Drilon, A., Hellmann, M. D., Reales, D. N., Benayed, R., Rusch, V. W., Kris, M. G., Chaft, J. E., Baselga, J., Taylor, B. S., Schultz, N., Rudin, C. M., Hyman, D. M., Berger, M. F., Solit, D. B., Ladanyi, M., & Riely, G. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- 6Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Corresponding author
- Riely, Gregory J.
- ORCID
- Jordan, Emmet J.
- Kim, Hyunjae R.
- Arcila, Maria E.
- Chakravarty, Debyani
- Gao, JianJiong
- Kundra, Ritika
- Jonsson, Philip
- Jayakumaran, Gowtham
- Zehir, Ahmet
- Rekhtman, Natasha
- Ginsberg, Michelle S.
- Li, Bob T.
- Yu, Helena A.
- Paik, Paul K.
- Drilon, Alexander
- Hellmann, Matthew D.
- Reales, Dalicia N.
- Benayed, Ryma
- Rusch, Valerie W.
- Kris, Mark G.
- Chaft, Jamie E.
- Taylor, Barry S.
- Schultz, Nikolaus
- Rudin, Charles M.
- Hyman, David M.
- Berger, Michael F.
- Solit, David B.
- Ladanyi, Marc
- Riely, Gregory J.
- Venue
- Cancer Discovery
- Published
- 2017-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 596-609
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5482929
- OpenAlex
- W2603411876
- Cited by
- 643
- References
- 49
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 65 · 2023: 99 · 2022: 94 · 2021: 101 · 2020: 79 · 2019: 65 · 2018: 55 · 2017: 12
- FWCI
- 47.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR002384)
- National Cancer Institute (P30CA008748)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, metastatic lung cancer, actionable mutations, targeted therapy, predictive biomarkers, drug response, STK11, Keap1, clinical benefit, molecular profiling
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Adolescent, Adult, Aged, Female, Genetic Testing, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Biomarkers, Tumor, Young Adult, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
